ANGPTL3 remained significantly associated with an increased risk for CV events following adjustment for age, gender, and BMI (adjusted HR 1.003, 95% CI: 1.002–1.005; P < 0.001) as well as following additional adjustment for DM, hypertension, fasting glucose, TCH, TG, LDL-C, eGFR, statin used, serum CRP level, and severity of baseline CAD (adjusted HR 1.003, 95% CI: 1.000–1.005; P=0.026). This evidence concerns the gene ANGPTL3 and hypertensive disorder.